The COVID-19 Long Haul Foundation

Treatment, Referral & Educational Support for COVID-19 Illnesses & Vaccine Injury

Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease

Laurent Chouchana 1,∗, Laure-Hélène Preta 1, Mylène Tisseyre 1, et. al., PMCID: PMC7907730  PMID: 33647327 Remdesivir is a novel adenosine-like nucleotide analogue, representing the first drug approved for coronavirus disease 2019 (COVID-19), albeit an uncertain clinical relevance. In […]

Idiopathic Retroperitoneal Hematoma Associated With Anticoagulation in a Patient With Moderate COVID-19 Pneumonia

Hikaru Murooka • Natsumi Yamamoto • Shiho Amano •, et. al. DOI: 10.7759/cureus.87395  Abstract We report a case of idiopathic retroperitoneal hematoma in an 82-year-old man with moderate COVID-19 pneumonia receiving prophylactic anticoagulation therapy. The patient […]

Remdesivir’s Known History of Lethality, Continues to Blame COVID-19 for the Deaths of Service Members and Veterans

by J.M. Phelps Gateway Pundit Using data from the Department of Defense (DOD) Joint Trauma System (JTS), The Remdesivir Papers came to life on October 4, 2024. In the 5,400-word report by J.M. Phelps […]

COVID-19 Therapeutics for Nonhospitalized Patients

Rajesh T. Gandhi, MD1; Preeti N. Malani, MD, MSJ2,3; Carlos del Rio, MD4, JAMA. 2022;327(7):617-618. doi:10.1001/jama.2022.0335 Substantial progress has been made in therapeutics for nonhospitalized patients with COVID-19, but supply of and access to treatment remain limited. This Viewpoint […]

Contributors BC, CW, and YeW had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the […]